Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BA Folic acid analogues
L01BA05 Pralatrexate
D05589 Pralatrexate (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Pralatrexate
D05589 Pralatrexate (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4229 Others
D05589 Pralatrexate (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01978 Folic acid analog
DG01930 Dihydrofolate reductase inhibitor
D05589 Pralatrexate
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D05589 Pralatrexate
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dihydrofolate reductase
DHFR
D05589 Pralatrexate (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05589
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05589
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05589